Despite the negative results, they suggest that PCSK9 inhibitors may have a threshold effect on the modulation of the immune response after stroke, which needs to be further validated in a larger cohort combining transcriptomics with functional immunoassays. The gene discussed is PCSK9; the disease is stroke disorder.